

Clinical study of a range of soft contact lens brands

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
09/08/2024	Recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
16/08/2024	Ongoing	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
29/12/2025	Eye Diseases	<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The aim of this study is to confirm the current safety and effectiveness of sphere, toric, and multifocal lenses compared to similar marketed devices and to address the long-term safety and performance of daily wear in users of these lenses. The choice of lenses was made to assess the clinical performance of the test lenses against currently marketed state-of-the-art products for the same indication.

Who can participate?

Patients aged between 8 and 75 years old who are current wearers of CE-marked CooperVision test or control lenses. Equivalent private-label contact lenses can be included in either group (for at least 6 months)

What does the study involve?

The participants will attend the clinic for one study visit wearing the study test or control lenses. The visit will be about 2 hours long during which participants will complete a questionnaire, have their vision measured, the contact lens fit evaluated, and their eyes examined. In addition, the investigator will review participant clinical notes available at the practice site to identify any adverse events associated with wearing study test or control lenses.

What are the possible benefits and risks of participating?

There may not be direct benefits to the participants, but participation may contribute to scientific information that may be used in the development of new contact lens products. The knowledge gained from this study may lead to important conclusions regarding the real-world safety and effectiveness of these lenses. The potential risks are minimal so the benefit-risk ratio is acceptable. Participants will already be routinely wearing these lenses so this is considered a non-significant risk study. Routine non-invasive procedures will be conducted in this study.

Where is the study run from?

Eurolens (UK)

When is the study starting and how long is it expected to run for?

December 2023 to April 2026

Who is funding the study?
CooperVision Inc., Ltd (USA)

Who is the main contact?
1. Archana Binod-Nair, archana.binod-nair@coopervision.co.uk
2. Sandhya Shekar, Sandhya.Shekhar@coopervision.co.uk

Contact information

Type(s)

Public

Contact name

Mrs Archana Binod-Nair

Contact details

CooperVision, R&D Facility, 36 School Lane, Chandler's Ford
Eastleigh
United Kingdom
SO53 4LY
+44 (0)7974 858 818
archana.binod-nair@coopervision.co.uk

Type(s)

Scientific

Contact name

Miss Sandhya Shekar

Contact details

CooperVision, R&D Facility, 36 School Lane, Chandler's Ford
Eastleigh
United Kingdom
SO53 4LY
+44 (0)7974899374
Sandhya.Shekhar@coopervision.co.uk

Type(s)

Principal investigator

Contact name

Prof Philip Morgan

Contact details

Eurolens Research
The University of Manchester
Manchester
United Kingdom

M13 9PL
+44 (0)161 306 4441
philip.morgan@manchester.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CV-23-91

Study information

Scientific Title

This study aims to assess the post-market safety and performance of a range of contact lens types

Study objectives

The objective of this post-market study is to demonstrate acceptable safety and effectiveness (performance) of a range of CooperVision soft contact lens types compared with similar marketed devices, when used in the general population.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 02/07/2024, University Research Ethics Committees (URECs) (2nd Floor, The Christie Building, The University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom; +44 (0)161 306 6000; urec1@manchester.ac.uk), ref: 2024-20572-36344

Study design

Prospective single-visit open-label observational study

Primary study design

Observational

Study type(s)

Efficacy, Safety

Health condition(s) or problem(s) studied

Myopia, astigmatism, hyperopia, presbyopia

Interventions

Recruitment:

Subjects will be recruited from the site's own patient listings based in England and Scotland.

Consenting:

Informed consent shall be obtained in writing from adult subjects, as well as assent and parental permission/consent from minors and their parent or legal guardian. The process shall be performed by an appropriately trained/delegated study member and will be documented before any procedure specific to the clinical investigation is carried out. The study members will be trained in the conduct of clinical research, show willingness to follow the study protocol and will be trained in GCP and the study protocol before commencing the study.

The potential participant will attend the clinic for one study visit wearing the study test or control lenses. The visit will be about 2 hours long during which participants will be consented to participate in the study, complete a questionnaire, have their vision measured, the contact lens fit evaluated, and their eyes examined. In addition, the investigator will review participant clinical notes available at the practice site to ensure that any adverse events associated with wearing study tests or control lenses that may have occurred are identified and analysed.

Please find below a list of the contact lenses 'or similar' tested:

Avaira Vitality Sphere

Proclear Sphere

Biomedics 55 Asphere

Biomedics Now Sphere

Avaira Vitality Toric

Proclear Toric and Toric XR

Biomedics Toric

Proclear Multifocal and Multifocal XR

Proclear Multifocal Toric

Clariti 1 day Daily Disposable Sphere

Biomedics 1 Day Extra-1 Day Sphere

Proclear - 1 Day – Sphere

Live 1 day

Clariti 1 day Daily Disposable Toric

Biomedics 1 Day Toric and EXTRA Toric

Clariti 1 day Daily Disposable Multifocal

Proclear 1 Day Multifocal

The acceptance and performance of the contact lenses will be tested for efficacy as per ISO11980-2012:

1. Measurement of contact lens logMAR visual acuity
2. Subjective rating of comfort, vision and handling
3. Subjective rating of contact lens fit and contact lens surface characteristics

The performance will be tested for safety as per ISO11980-2012:

1. Identification of ocular adverse events related to contact lens wear
2. Measurement of spectacle logMAR visual acuity
3. Assessment of the ocular tissues and ratings as per ISO11980-2012 scales

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Range of soft contact lens brands

Primary outcome(s)

1. Visual performance (visual acuity) measured based on high-contrast visual acuity at one timepoint
2. Incidence of contact lens-related adverse events measured using subject reports and slit lamp evaluation

Key secondary outcome(s)

Relationship determination between lens fit, surface measurements, and subjective scores measured using appropriate statistical modeling, slit lamp evaluation, and VAS/ISO Questionnaires at one timepoint

Completion date

30/04/2026

Eligibility

Key inclusion criteria

1. Age 8 to 75 years (inclusive)
2. They understand their rights as a research subject and are willing to sign a Statement of Informed Consent
3. Current wearer (for at least 6 months) of CE-marked CooperVision test or control lenses. Equivalent private-label contact lenses can be included in either group

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

8 years

Upper age limit

75 years

Sex

All

Total final enrolment

0

Key exclusion criteria

Participation in a contact lens or contact lens care product clinical trial within the previous 30 days

Date of first enrolment

01/08/2024

Date of final enrolment

30/04/2026

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre**Eurolens Research**

The University of Manchester
Oxford Road
Manchester
England
M13 9PL

Sponsor information

Organisation

CooperVision Inc Ltd

Funder(s)

Funder type

Industry

Funder Name

CooperVision

Alternative Name(s)

CooperVision, Inc., CooperVision Inc, CooperVision Inc., CooperVision, Inc

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Participant information sheet</u>	Participant information sheet	11/11/2025	11/11/2025	No	Yes